

Elevation Oncology, a developer of precision medicines for patients with genomically defined cancers, has raised $65 million in Series B financing. The lead backers were venBio Partners and Cormorant Asset Management.
Source: Press Release
Elevation Oncology, a developer of precision medicines for patients with genomically defined cancers, has raised $65 million in Series B financing.
Elevation Oncology, a developer of precision medicines for patients with genomically defined cancers, has raised $65 million in Series B financing. The lead backers were venBio Partners and Cormorant Asset Management.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination